Lupin the domestic pharma major has launched its generic version of Moxifloxacin Hydrochloride Ophthalmic solution in the US market which is used in treating bacterial conjunctivitis.

The company has said in a statement that the launch follows receipt of approval from the US Food and Drug Administration (USFDA) earlier for Moxifloxacin Hydrochloride Ophthalmic solution 0.5 percent.

It added that the product is produced at Lupin’s Pithampur manufacturing facility.

Read EquityPandit’s Technical Analysis on Nifty Pharma